Le Lézard
Classified in: Health, Science and technology, Business
Subjects: ERN, ACC

Tobii Dynavox Year-End Report 2023


STOCKHOLM, Feb. 8, 2024 /PRNewswire/ -- Tobii Dynavox AB (publ) today announced its results for the fourth quarter and full year of 2023. 

Comment from the Tobii Dynavox CEO Fredrik Ruben:

"Our strong performance throughout 2023 continues, characterized by a substantial growth in sales and a more than doubled operating profit in the closing quarter of the year. As previously, growth was solid across all geographical areas and user groups. To realize our long-term growth potential, we are committed to investing in new staff, skills and tools to boost the scalability of the business. The low level of awareness regarding communication aids among prescribers and potential users presents an enormous opportunity for us to make a meaningful difference, while also significantly growing our business."

QUARTER: OCTOBER - DECEMBER 2023   

PERIOD JANUARY ? DECEMBER 2023  

SIGNIFICANT EVENTS DURING THE QUARTER 

Åsa Hedin, Chair of the Board of Directors of Tobii Dynavox, informed the Nomination Committee on December 11 that she will not stand for re-election at the 2024 Annual General Meeting. The Nomination Committee has therefore initiated the recruitment process to find her successor.

Comments from the CEO:

"Our strong performance throughout 2023 continues, characterized by a substantial growth in sales and a more than doubled operating profit in the closing quarter of the year. As previously, growth was solid across all geographical areas and user groups. To realize our long-term growth potential, we are committed to investing in new staff, skills and tools to boost the scalability of the business. The low level of awareness regarding communication aids among prescribers and potential users presents an enormous opportunity for us to make a meaningful difference, while also significantly growing our business. 

Sales growth continued to be robust in the last quarter of the year. Denominated in local currency, it was just over 30 percent for the quarter and 27 percent for the full year. In the US, the upward adjustment of reimbursement rates by Medicare for our products, 9 percent for 2023, was fully reflected in the fourth quarter. In 2024, the equivalent increase will be 2.6 percent. We continue to see substantial growth across all customer types and product categories. Sales to user groups that benefit from symbol-based communication, typically children or younger users with autism diagnoses, are however growing faster than other user groups. The past several quarters clearly demonstrate that the benefits of scale in our business translates topline growth into increased operating margin. We expect this trend to continue as sales grows even further. 

Acquisitions is an integral part of our growth journey, and we place significant emphasis on business logic and synergies when assessing potential candidates. The integration of our longstanding German supplier partner Rehadapt, a transaction finalized in early September, is progressing well. The company seamlessly complements our offering with its mounting solutions for communication aids, while also strengthening our position in Germany.  

Our growth is driven by a number of factors. The synergy of our robust product offering and committed employees, coupled with a market in its early phases with minimal penetration, points to significant long-term potential. In practice, awareness about the communication aids that we and our industry peers can offer never reaches the majority of people in need of assistive technology. This situation remains true even in the most developed countries. The root cause is the lack of knowledge about communication aids among the key groups responsible for prescribing them: speech-language pathologists and occupational therapists. In many cases, relevant training related to the available assistive technology is either non-existent or severely limited. Our commitment to large scale training initiatives are an important contribution to this.

Against the backdrop of two million new cases diagnosed worldwide annually, we have supplied around 25,000 more communication aids in 2023 compared with the previous year. While it is indeed gratifying that we can assist more individuals, the increase represents only a fraction of the estimated number of new cases where individuals require assistive communication aids. For example, in the US, our largest market by far, the proportion of speech-language pathologists who have prescribed a communication aid at least once per year is barely 5 percent of the professional community. 

I am convinced that our historically robust growth in 2023 is a direct outcome of our long-term efforts to educate and share knowledge about the products and solutions we can offer, combined with their meaningful impact on the lives of users and their families. When coupled with our strong market position, this indicates that our long-term business potential is considerable even though building competence and awareness can be categorized as more of a marathon than a sprint. With a substantial dose of humility, particularly directed at our fantastic organization, we bring the record year of 2023 to a close, while maintaining a strong sense of confidence in the future.

Join us on February 21 for a Capital Markets Day in Stockholm, where we will offer a more in-depth presentation of our business and future strategy."

Fredrik Ruben, CEO

Webcast:

Today at 9:00 a.m. CET, Tobii Dynavox will host a webcast presentation for media, analysts and investors. If you want to attend the webcast click the following link. The year-end report and a recording of the webcast will be available here after the webcast.

This information is inside information that Tobii Dynavox AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 07.30 CET on Feb 8, 2024.

Contact
Linda Tybring, CFO, Tobii Dynavox, phone: +46 (0) 7068 14 980, email: [email protected]

The following files are available for download:

https://mb.cision.com/Main/11919/3924679/2590530.pdf

Tobii Dynavox AB Interim Report Q4 2023_FINAL

https://mb.cision.com/Public/11919/3924679/b0f7da0fdc93fbb6.pdf

Press release Tobii Dynavox year-end report 2023

 

SOURCE Tobii Dynavox


These press releases may also interest you

1 mai 2024
Today, a decision was issued by the Court of Appeals Division I in the State of Washington in Erickson v. Monsanto, ruling in Monsanto's favor on multiple grounds. This decision reverses the initial verdict of $185 million in its entirety and...

1 mai 2024
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Poseida Therapeutics, Inc.  today announced that Xyphos Biosciences, Inc., (a wholly owned subsidiary of Astellas, "Xyphos") and Poseida have entered into a...

1 mai 2024
Memorial Regional Hospital in Florida has earned the prestigious title of being the state's inaugural Resuscitation Center of Excellence (RCOE), underscoring the hospital's adherence to over 30 evidence-based criteria in providing top-tier cardiac...

1 mai 2024
Momcozy, a trusted global brand specializing in solution-focused maternal and baby care products since 2018, has announced their collaboration with 1 Natural Way (1NW), a nationally recognized Durable Medical Equipment company catering to the precise...

1 mai 2024
Infinitopes Precision Immunomics, an integrated cancer biotech combining world leading platforms in precision antigen discovery with vaccine vectors capable of durably stimulating protective immune responses, today announced the completion of a...

1 mai 2024
The ALS Association today celebrated the beginning of ALS Awareness Month and the 10th Anniversary of the Ice Bucket Challenge, which inspired the world to join the fight against ALS in the summer of 2014. Throughout May and the summer, the ALS...



News published on and distributed by: